Navigation Links
Safeguard® Sealident® Super-Wide Wristbands

ProductsSafeguard® Sealident® Super-Wide Wristbands
Company Precision Dynamics Corporation
Item Safeguard® Sealident® Super-Wide Wristbands
Features 
  • Ultra stretch-resistant tri-laminate band comes with a secure adhesive closure.
  • Water-resistant pocket enclosure protects labels from smearing, wrinkling, and scratching.
  • Insert cards (included) accept up to 6 lines of data and labels up to 1 wide.
  • Custom imprinting available upon request.
  • Will accommodate a 1" wide bar code label. Note: Recommended labels: 9130, 9132, 9100, 9110.
Description Use these popular insert style bands to secure a bar code label inside the wristband pocket for maximum convenience and security.
Info Precision Dynamics Corporation
Customer Service: (818) 897-1111
Web site: http://www.pdcorp.com

Related medicine products :

1. Sentinel™ Bar Coded Patient Id Wristbands
2. CompuBand® Thermal Printing Lanyard Snap Wristbands
3. ScanBand and Sentinel Direct Thermal Wristbands
4. Thermal Transfer Wristbands
5. Securline® Bar Code Band Wristbands
6. PrimeBand® Wristbands
7. DataMate Laser Label Sheets for Insert Wristbands
8. DataMate Mother/Father/Infant Laser Wristbands
9. DataMate Laser Label Sheets for Adhesive Label Wristbands
10. Zebra Barcode Wristbands
...atory system for pH and temperature measurements. ... when used with a temperature probe (ATC) or a 3-i...int calibration with Auto-Find automatic buffer re...0.01 and 12.45) and Auto-Read for locking onto sta...
...atory system for pH and temperature measurements. ... when used with a temperature probe (ATC) or a 3-i...int calibration with Auto-Find automatic buffer re...0.01 and 12.45) and Auto-Read for locking onto sta...
...atory system for pH and temperature measurements. ... when used with a temperature probe (ATC) or a 3-i...int calibration with Auto-Find automatic buffer re...0.01 and 12.45) and Auto-Read for locking onto sta...
...tional high-end microplate reader with outstanding... modes., Fluorescence Intensity - FRET , Fluores... HTRF, AlphaScreen , Luminescence , , , PHERAst...der with fastest read times. The ultimate solution...
Medicine Products:
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...ed later this month at the World Health Organizati...dvertisements targetting// children. The draft WH...ussed on vulnerable groups such as children and ad...be exploited by commercial activities." It calls f...
... cancer retinoblastoma has been developed by scien... demonstrated// in a mouse model to cause a remark...ausing the side effects common with standard chemo...o be suitable for certain forms of breast, lung, p...
... an expectant mother does not play an important ro...a low-weight baby.// Since one in ten babies are b...s them prone to a host of health problems, that in...tists thought it imperative to examine if treating...
...s year, an estimated 151 million doses, its distri... Family Practice, for instance ordered 750 doses b...ay. On the other hand at York Hospital, 9,000-plus...John Phylis, director of pharmacy for York hospita...
Other Medicine News:Health News:Stop Exploiting Children ! Anti Obesity Charter On Junk Food Ads 2Health News:Revolutionary Eye Cancer Treatment 2Health News:Revolutionary Eye Cancer Treatment 3Health News:Revolutionary Eye Cancer Treatment 4Health News:Distribution of Flu Vaccines Unpredictable 2
(Date:9/3/2008)... September is National Vascular Disease Awareness ... -- Diffusion Pharmaceuticals,LLC, a clinical-stag...gs,for the treatment of unmet medical needs, annou... a Phase I/II clinical trial of its lead drug,cand...esignated NCT00725881,on the clinicaltrials.gov We...
(Date:9/3/2008)...RSBURG, Md., Sept. 3 /- Panacea Pharm....S. Patent Number 7,413,737 covering,antibodies ag...e (HAAH), a,proprietary human cancer biomarker and...ed in collaboration with the Massachusetts Institu...worldwide rights to this patent,for development of...
(Date:9/3/2008)... Company to Discuss Phase 3 Plans with FDA, ...erapeutics, Inc.,announced today that it successf...lopment of the company,s new, innovative low-dose,...ny refers to by its internal product,code AG-200-1...ully met its,primary endpoint of ovulation suppres...
(Date:9/3/2008)...nical Trial Reconfirms Strong Evidence Pycnogenol(...ing Effect on Joints Following Cessation ... Sept. 3 /- According to the Center f... common type of arthritis,is on the rise. A new s...py,Research, reveals Pycnogenol(R), bark extract f...
Breaking Medicine Technology:Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4California Stem Cell Agency Proposes Unjustified Increase in Top Salary Ranges 12240 1California Stem Cell Agency Proposes Unjustified Increase in Top Salary Ranges 12240 2Novavax Enters Into Estrasorb 28R 29 Asset Sale and Supply Agreements with Graceway Pharmaceuticals LLC 3387 1Novavax Enters Into Estrasorb 28R 29 Asset Sale and Supply Agreements with Graceway Pharmaceuticals LLC 3387 2Novavax Enters Into Estrasorb 28R 29 Asset Sale and Supply Agreements with Graceway Pharmaceuticals LLC 3387 3New Guacamole 100 Calorie Packs The Solution for Clashing February Holidays 12233 1New Guacamole 100 Calorie Packs The Solution for Clashing February Holidays 12233 2B Line Medical and Immersion Medical Announce Partnership 3385 1B Line Medical and Immersion Medical Announce Partnership 3385 2B Line Medical and Immersion Medical Announce Partnership 3385 3
...ne 04, 2007 /PRNewswire-FirstCall/ -- Kosan,Biosci... a Phase 2,monotherapy trial showing that tanespim...ity in patients with metastatic melanoma,includin... failed,prior chemotherapy (within 6 weeks of init...gression-free survival for more than,six months an...
...ne 04, 2007 /PRNewswire-FirstCall/ -- Kosan,Biosci...linical,trial showing that KOS-1584/R1645, an epot...ed promising antitumor,activity and tolerability i...d activity in 32% of patients (13 of 41,evaluable)...l lung,ovarian, breast, prostate, head and neck a...
Other Medicine Technology:Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 2Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 3Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 4Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 2Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 3Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 4Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 5